{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:51:14Z","timestamp":1783673474258,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20240731"],"award-info":[{"award-number":["BK20240731"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaip.2025.02.035","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T23:53:44Z","timestamp":1741305224000},"page":"1664-1678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular Risk of the Use of Long-Acting Bronchodilators in Patients With Asthma: A Meta-Analysis of 22 Randomized Controlled Trials"],"prefix":"10.1016","volume":"13","author":[{"given":"Le","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.02.035_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-2600(15)00518-4","article-title":"Cardiac effects of current treatments of chronic obstructive pulmonary disease","volume":"4","author":"Lahousse","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2165\/00003495-200565120-00001","article-title":"Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease","volume":"65","author":"Cazzola","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2025.02.035_bib3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1517\/14740338.2010.500611","article-title":"The cardiovascular risk of tiotropium: is it real?","volume":"9","author":"Cazzola","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2025.02.035_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","article-title":"Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study","volume":"178","author":"Wang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","article-title":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","volume":"173","author":"Gershon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib6","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.mayocp.2018.05.030","article-title":"Risk of severe cardiovascular events from add-on tiotropium in chronic obstructive pulmonary disease","volume":"93","author":"Liou","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaip.2025.02.035_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00302-2022","article-title":"Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis","volume":"61","author":"Yang","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.02.035_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","article-title":"Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"3","author":"Chen","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1183\/09059180.00008612","article-title":"Comorbidities of COPD","volume":"22","author":"Cavaill\u00e8s","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2025.02.035_bib10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaip.2024.02.001","article-title":"The relationship between allergic rhinitis, asthma, and cardiovascular disease in the National Health Interview Surveys (NHIS), 1999-2018","volume":"12","author":"Nagarajan","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.035_bib11","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.chest.2020.11.053","article-title":"The relationship between asthma and cardiovascular disease: an examination of the Framingham Offspring Study","volume":"159","author":"Pollevick","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.02.035_bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jaip.2019.06.043","article-title":"Risk of acute myocardial infarction and ischemic stroke in patients with asthma exacerbation: a population-based, self-controlled case series study","volume":"8","author":"Raita","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.035_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jaip.2016.02.018","article-title":"Asthma status and risk of incident myocardial infarction: a population-based case-control study","volume":"4","author":"Bang","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.035_bib14","author":"Higgins"},{"key":"10.1016\/j.jaip.2025.02.035_bib15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2025.02.035_bib16","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2025.02.035_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12874-015-0031-0","article-title":"Meta-analysis of incidence rate data in the presence of zero events","volume":"15","author":"Spittal","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2025.02.035_bib18","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.jaip.2025.02.035_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2025.02.035_bib20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2025.02.035_bib21","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1185\/03007990802119111","article-title":"Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone","volume":"24","author":"Bailey","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2025.02.035_bib22","doi-asserted-by":"crossref","first-page":"e006131","DOI":"10.1136\/bmjopen-2014-006131","article-title":"Effect of once-daily indacaterol maleate\/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial","volume":"5","author":"Beasley","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2025.02.035_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1081-1206(10)62351-4","article-title":"A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler","volume":"86","author":"Bensch","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.02.035_bib24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/02770903.2017.1386214","article-title":"Once-daily fluticasone furoate\/vilanterol versus twice-daily fluticasone propionate\/salmeterol in patients with asthma well controlled on ICS\/LABA","volume":"55","author":"Bernstein","year":"2018","journal-title":"J Asthma"},{"key":"10.1016\/j.jaip.2025.02.035_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2012.03.028","article-title":"Long-term safety and asthma control measures with a budesonide\/formoterol pressurized metered-dose inhaler in African American asthmatic patients: a randomized controlled trial","volume":"130","author":"Brown","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.035_bib26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1378\/chest.115.3.642","article-title":"Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial","volume":"115","author":"Chervinsky","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.02.035_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.clinthera.2007.05.011","article-title":"Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma","volume":"29","author":"Corren","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2025.02.035_bib28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.119.3.714","article-title":"Effectiveness and safety of salmeterol in nonspecialist practice settings","volume":"119","author":"D'Urzo","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.02.035_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2213-2600(15)00031-4","article-title":"Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials","volume":"3","author":"Kerstjens","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib30","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","article-title":"Tiotropium in asthma poorly controlled with standard combination therapy","volume":"367","author":"Kerstjens","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12931-020-01400-5","article-title":"A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids","volume":"21","author":"Kerwin","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2025.02.035_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.rmed.2007.12.002","article-title":"Efficacy and safety of fluticasone propionate\/salmeterol 250\/50 mcg Diskus administered once daily","volume":"102","author":"Kerwin","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.rmed.2005.09.006","article-title":"Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate","volume":"100","author":"Lundb\u00e4ck","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2500\/aap.2017.38.4061","article-title":"A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate\/salmeterol multidose dry powder inhalers in persistent asthma","volume":"38","author":"Mansfield","year":"2017","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.02.035_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1378\/chest.129.1.15","article-title":"The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol","volume":"129","author":"Nelson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.02.035_bib36","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2165\/00003495-200666170-00006","article-title":"Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial","volume":"66","author":"Noonan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2025.02.035_bib37","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1183\/09031936.00064513","article-title":"Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma","volume":"43","author":"O'Byrne","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.02.035_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124109","article-title":"Long-term once-daily tiotropium respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study","volume":"10","author":"Ohta","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2025.02.035_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2500\/aap.2008.29.3147","article-title":"Long-term safety and asthma control with budesonide\/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients","volume":"29","author":"Peters","year":"2008","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2025.02.035_bib40","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1056\/NEJMoa1511049","article-title":"Serious asthma events with fluticasone plus salmeterol versus fluticasone alone","volume":"374","author":"Stempel","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib41","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2213-2600(20)30178-8","article-title":"Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study","volume":"8","author":"van Zyl-Smit","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib42","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaci.2018.10.065","article-title":"Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate","volume":"143","author":"Weinstein","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.035_bib43","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","article-title":"Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis","volume":"125","author":"Salpeter","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2025.02.035_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00408-013-9525-x","article-title":"Cardiovascular safety of long acting beta agonist-inhaled corticosteroid combination products in adult patients with asthma: a systematic review","volume":"192","author":"Iftikhar","year":"2014","journal-title":"Lung"},{"key":"10.1016\/j.jaip.2025.02.035_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106311","article-title":"Cardiovascular safety of mometasone\/indacaterol and mometasone\/indacaterol\/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials","volume":"180","author":"Scosyrev","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.02.035_bib46","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.02.035_bib47","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1161\/ATVBAHA.115.305452","article-title":"Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis","volume":"35","author":"Tattersall","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825002089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825002089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:17:12Z","timestamp":1762607832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825002089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2213219825002089"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.02.035","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Risk of the Use of Long-Acting Bronchodilators in Patients With Asthma: A Meta-Analysis of 22 Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}